Loading company…
Dutch biotech developing RNA-modulating antisense drugs for genetic neurological disorders such as Huntington's.
Founded in 2019 and based in South Holland, Netherlands, Vico Therapeutics B.V. develops RNA modulation therapies for genetic neurological disorders, led by CEO Micah Mackison. Its lead product, VO659, is an antisense oligonucleotide that targets CAG repeat expansions in polyglutamine disorders, including spinocerebellar ataxia type 3, spinocerebellar ataxia type 1 and Huntington's disease. In June 2024 the company raised EUR 11.5 million in Series B funding co-led by Seroba Life Sciences and Kurma Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in